Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Preferred Stock Liabilities (2020 - 2021)

Cytek Biosciences' Preferred Stock Liabilities history spans 2 years, with the latest figure at $194.3 million for Q2 2021.

  • For Q2 2021, Preferred Stock Liabilities changed N/A year-over-year to $194.3 million; the TTM value through Jun 2021 reached $194.3 million, changed N/A, while the annual FY2020 figure was $194.3 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $194.3 million in Q2 2021 per CTKB's latest filing, roughly flat from $194.3 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $194.3 million in Q4 2020 to a low of $194.3 million in Q4 2020.